000310011 001__ 310011
000310011 005__ 20260223120902.0
000310011 0247_ $$2doi$$a10.1002/path.70039
000310011 0247_ $$2pmid$$apmid:41716034
000310011 0247_ $$2ISSN$$a0368-3494
000310011 0247_ $$2ISSN$$a0022-3417
000310011 0247_ $$2ISSN$$a1096-9896
000310011 0247_ $$2ISSN$$a1555-2039
000310011 037__ $$aDKFZ-2026-00424
000310011 041__ $$aEnglish
000310011 082__ $$a610
000310011 1001_ $$00000-0002-0070-3158$$aReitsam, Nic G$$b0
000310011 245__ $$aDeep learning-based H&E-derived risk scores in colorectal cancer: associations with tumour morphology, biology, and predicted drug response.
000310011 260__ $$aBognor Regis [u.a.]$$bWiley$$c2026
000310011 3367_ $$2DRIVER$$aarticle
000310011 3367_ $$2DataCite$$aOutput Types/Journal article
000310011 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771842278_3895551
000310011 3367_ $$2BibTeX$$aARTICLE
000310011 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000310011 3367_ $$00$$2EndNote$$aJournal Article
000310011 500__ $$aepub
000310011 520__ $$aOver recent years, several deep learning (DL) models have been presented to predict colorectal cancer (CRC) patient survival directly from haematoxylin and eosin (H&E)-stained routine whole-slide images (WSIs). Unlike traditional studies that rely on manually defined histopathological features, weakly supervised DL allows training directly on clinical endpoints without prior specification of the model's focus. This offers a unique opportunity to study the tissue morphology underlying these predictions, improving our understanding of disease biology. Here, we present a comprehensive analysis of the clinicopathological features, tumour morphology and biology, as well as gene expression-based predicted drug response of over 4,000 CRC patients derived from four different international cohorts with available H&E-inferred DL-based risk scores (low- versus high-risk as well as absolute risk scores). The results from our study suggest that conventional clinicopathological risk factors, such as grade of differentiation, presence of lymph node metastasis, tumour budding, and percentage of tumour necrosis, are positively associated with DL-based risk scores. Moreover, CRCs with direct tumour-adipocyte interactions are enriched in the DL-based high-risk group. Through detailed morphologic review, we provide comprehensive evidence that direct tumour-adipocyte interaction, a high degree of tumour budding, and poorly differentiated morphology are linked to high DL-based risk scores. Transcriptomic and genetic subgroups show only limited association with H&E-derived DL-based risk scores. Moreover, we present data suggesting that DL-based low- versus high-risk CRCs may be characterised by differential drug sensitivity. Our study highlights that DL-based risk scores derived from H&E WSIs not only align with established clinicopathological features but also highlight morphological features, such as tumour-adipocyte interaction, that are not routinely captured by established clinicopathological scoring systems. Moreover, DL-based risk groups may be associated with a differential treatment response, underlining their potential to guide patient stratification in routine clinical practice. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
000310011 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000310011 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000310011 650_7 $$2Other$$abiomarker
000310011 650_7 $$2Other$$acolorectal cancer
000310011 650_7 $$2Other$$acomputational pathology
000310011 650_7 $$2Other$$adeep learning
000310011 650_7 $$2Other$$adrug response
000310011 650_7 $$2Other$$agene expression
000310011 650_7 $$2Other$$ahistopathology
000310011 650_7 $$2Other$$apathology
000310011 650_7 $$2Other$$awhole‐slide image
000310011 7001_ $$aJiang, Xiaofeng$$b1
000310011 7001_ $$aLiang, Junhao$$b2
000310011 7001_ $$aGrosser, Bianca$$b3
000310011 7001_ $$00000-0002-0825-7383$$aGrozdanov, Veselin$$b4
000310011 7001_ $$aLoeffler, Chiara Ml$$b5
000310011 7001_ $$00009-0009-3598-5720$$aGustav, Marco$$b6
000310011 7001_ $$00000-0002-9034-2535$$aLenz, Tim$$b7
000310011 7001_ $$aMuti, Hannah S$$b8
000310011 7001_ $$aCarrero, Zunamys I$$b9
000310011 7001_ $$00000-0002-0346-6709$$aWest, Nicholas P$$b10
000310011 7001_ $$00000-0002-3597-5444$$aQuirke, Philip$$b11
000310011 7001_ $$aFoersch, Sebastian$$b12
000310011 7001_ $$aJesinghaus, Moritz$$b13
000310011 7001_ $$aMüller, Wolfram$$b14
000310011 7001_ $$0P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aYuan, Tanwei$$b15$$udkfz
000310011 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b16$$udkfz
000310011 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b17$$udkfz
000310011 7001_ $$aJonnagaddala, Jitendra$$b18
000310011 7001_ $$aHawkins, Nicholas J$$b19
000310011 7001_ $$aWard, Robyn L$$b20
000310011 7001_ $$00000-0001-9520-6228$$aGrabsch, Heike I$$b21
000310011 7001_ $$aMärkl, Bruno$$b22
000310011 7001_ $$aKather, Jakob N$$b23
000310011 773__ $$0PERI:(DE-600)1475280-3$$a10.1002/path.70039$$gp. path.70039$$pnn$$tThe journal of pathology$$vnn$$x0368-3494$$y2026
000310011 909CO $$ooai:inrepo02.dkfz.de:310011$$pVDB
000310011 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000310011 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000310011 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000310011 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000310011 9141_ $$y2026
000310011 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-12$$wger
000310011 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-12$$wger
000310011 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PATHOL : 2022$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-12
000310011 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ PATHOL : 2022$$d2025-11-12
000310011 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000310011 9201_ $$0I:(DE-He78)M320-20160331$$kM320$$lKoordinierungsstelle der Cancer Prevention GS$$x1
000310011 980__ $$ajournal
000310011 980__ $$aVDB
000310011 980__ $$aI:(DE-He78)C070-20160331
000310011 980__ $$aI:(DE-He78)M320-20160331
000310011 980__ $$aUNRESTRICTED